We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Neurotune and NiKem Research Srl Enter into a Research Service Agreement

News   Apr 02, 2007

 
Neurotune and NiKem Research Srl Enter into a Research Service Agreement
 
 
Advertisement
 

RELATED ARTICLES

Team Identifies Potential Pitfall in Emerging Treatment for Cancer and Inflammation

News

Whilst studying an emerging drug target in cancer and inflammation, researchers discovered the unintended activation of a protein called ERK5, this activation was due to the binding location of the inhibitors. ERK5 inhibitors that bound to the kinase domain of the protein led to the protein being shuttled to the cell nucleus and activated. Blocking ERK5 has therapeutic potential, but activating it could have undesirable consequences in terms of stimulated unwanted cell growth.

READ MORE

Collaborations Aim to Meet Unmet Clinical Needs in Biomarker Discovery and Characterization

News

Thermo Fisher Scientific announced agreements with AstraZeneca and the University of Nebraska Medical Center that will showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis.

READ MORE

COVID-19 Phase 3 Trial To Evaluate REGN-COV2 Antibody Cocktail in UK

News

RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world’s largest randomized clinical trials of potential COVID-19 treatments, will evaluate Regeneron’s investigational anti-viral antibody cocktail known as REGN-COV2. The Phase 3 open-label trial in patients hospitalized with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE